奥美拉唑,临床注释-2,变异和临床注释数据

奥美拉唑

临床注释ID

1183630065

药物名称(英)

omeprazole

变异单倍型

CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*9, CYP2C19*10, CYP2C19*17, CYP2C19*24, CYP2C19*26

基因

CYP2C19

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Metabolism/PK

表现型类别

代谢/PK

分数

228.8125

PMID计数

计数的证据

表现型

胃食管反流

表现型(英)

Gastroesophageal Reflux

最新日期

2021/5/3 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/1183630065

专业人口(英)

Pediatric

专业人口

儿科

临床等位基因

id	等位基因	注释文本
1050	*26	The CYP2C1926 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C1926 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.
1049	*24	The CYP2C1924 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C1924 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.
1048	*17	The CYP2C1917 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C1917 allele in combination with a normal or increased function allele may have increased metabolism of omeprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.
1047	*10	The CYP2C1910 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C1910 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.
1046	*9	The CYP2C199 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C199 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.
1045	*3	The CYP2C193 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C193 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.
1044	*2	The CYP2C192 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C192 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.
1043	*1	The CYP2C191 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C191 allele in combination with another normal function allele may have increased metabolism of omeprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of omeprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.

临床证据

id	证据的ID	总结
4877	1447963286	CYP2C19 1/2 is associated with decreased metabolism of mephenytoin or omeprazole in healthy individuals as compared to CYP2C19 1/1.
4876	1444696670	CYP2C19 10 is associated with decreased clearance of omeprazole as compared to CYP2C19 1.
4875	1444696659	CYP2C19 10 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 1.
4874	1184566038	CYP2C19 26 is associated with decreased clearance of mephenytoin and omeprazole as compared to CYP2C19 1.
4873	1184565887	CYP2C19 26 is associated with decreased metabolism of mephenytoin and omeprazole as compared to CYP2C19 1.
4872	1184564759	CYP2C19 26 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin and omeprazole as compared to CYP2C19 1.
4871	1184471092	CYP2C19 10 is associated with decreased catalytic activity of CYP2C19 when assayed with omeprazole in E. coli DH5alpha as compared to CYP2C19 1.
4870	1183624136	CYP2C19 2/3 is associated with decreased metabolism of mephenytoin or omeprazole in healthy individuals as compared to CYP2C19 1/1.
4869	1183623411	CYP2C19 1/1 is not associated with metabolism of omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 1/17.
4868	1183623395	CYP2C19 1/1 is not associated with metabolism of lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 1/2.
4867	1183619918	CYP2C19 1/2 + 1/3 is associated with increased metabolism of omeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 2/2 + 2/3 + 3/3.
4866	1183619889	CYP2C19 1/1 is associated with increased metabolism of omeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 2/2 + 2/3 + 3/3.
4865	655387742	Genotype TT is associated with decreased AUC of omeprazole in people with no disease as compared to genotype CC.
4864	655387718	Genotype TT is associated with increased metabolism of omeprazole in people with no disease as compared to genotype CC.
4863	1450807240	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole, omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.
4862	1450807931	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.
4861	1450807902	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.
4860	1450806946	CYP2C19 poor metabolizers are associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.
4859	1450806923	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.
4858	1450806689	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.
4857	1450370721	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.
4856	1450370714	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.
4855	PA166104957	Annotation of DPWG Guideline for omeprazole and CYP2C19
4854	PA166219103	Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19
3930	1447680365	CYP2C19 *9 is associated with decreased metabolism of omeprazole in healthy individuals.
3929	1450809604	CYP2C19 1/1 + 1/2 + 1/3 are associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 2/2 + 2/3 + 3/3.
3928	1450808537	CYP2C19 2/2 are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 1/1 + 1/2.
3927	1450807854	CYP2C19 1/1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 1/2 + 1/3 + 2/3.
3926	1450807702	CYP2C19 2/3 + 2/2 is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 1/1 + 1/2 + 1/3.
3925	1450807373	CYP2C19 1/1 is associated with increased metabolism of omeprazole in people with acid-related disorders as compared to CYP2C19 1/2 + 1/3 + 2/2.
3924	1450807307	CYP2C19 1/2 + 1/3 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 2/2 + 2/3 (assigned as normal metabolizers phenotype) .
3923	1450807298	CYP2C19 1/1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 1/2 + 1/3.
3922	1450806785	CYP2C19 1/1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 1/2 + 1/3 + 2/2 + 2/3 + 3/3.
3921	1450806762	CYP2C19 1/1 is not associated with metabolism of omeprazole in healthy individuals as compared to CYP2C19 1/2.
3920	1450806712	CYP2C19 2/2 is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 1/2 + 1/3 + 1/1.
3919	1449166259	CYP2C19 2 is associated with decreased clearance of omeprazole in infants with Gastroesophageal Reflux as compared to CYP2C19 1 + *17.
3918	1448263323	CYP2C19 24 is associated with decreased clearance of mephenytoin and omeprazole in E.coli as compared to CYP2C19 1.
3917	1447992028	CYP2C19 3 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 1.

临床病史

id	类型	评论
823	Update	Added DPWG guideline.
822	Update	CA score added as part of scoring system release. LOE assigned following curator review.
821	Update	Changed to level 1A because of CPIC PPI guideline
820	Update	Updated 'extensive metabolizer' term to 'normal metabolizer' following CPIC Term Standardization Project.
819	Update	Updated OMB race to appropriate biogeographical group
818	Update	Added PMID 29377228

最新招商产品更多>>